Am J Surg. 2018 Jul 19. pii: S0002-9610(18)30097-7. doi: 10.1016/j.amjsurg.2018.07.022. [Epub ahead of print]
Application of 21-gene recurrence score results and ASTRO suitability criteria in breast cancer patients treated with intraoperative radiation therapy (IORT).
Schwartzberg BS1, Chin DT2, Dorn PL3, Herron DS3, Howell KT2, Kemmis TJ4, Miller SA5, Moore JA6, Paul D7.
Abstract
BACKGROUND:
American Society for Radiation Oncology (ASTRO) suitability criteria for accelerated partial breast irradiation (APBI) and the 21-gene recurrence score (RS) were evaluated for prognostic and predictive benefit in IORT patients.
METHODS:
Outcomes of 184 patients completing IRB approved IORT protocol were retrospectively reviewed. Data included demographics, histopathology, RS, adjuvant therapy, locoregional (LRR) and distant recurrences (DR), and breast cancer-specific survival.
RESULTS:
There were 10 (5.4%) breast cancer recurrences, including one breast cancer-specific death. All 184 patients were classified by ASTRO suitability criteria (suitable: 64% (5 LRR), cautionary: 30% (3 LRR), unsuitable: 6.0% (1 LRR, 1 DR leading to death). RS were available in 114 estrogen receptor positive patients (<11: 22% (1 LRR), 11-25: 63% (1 LRR), 26-30: 9%, >30: 6%). Mean follow-up was 55 months.
CONCLUSIONS:
ASTRO suitability criteria for APBI and RS were useful in making prognostic and therapeutic recommendations for patients considering IORT.
Copyright © 2018 Elsevier Inc. All rights reserved.
KEYWORDS:
21-Gene recurrence score; ASTRO suitability criteria for APBI; Breast cancer; Intraoperative radiation therapy; Recurrences
- PMID:
- 30041733
- DOI:
- 10.1016/j.amjsurg.2018.07.022
.png)
No hay comentarios:
Publicar un comentario